Interrogating the potential of in vitro tools for predicting immunogenicity against novel modality therapeutics
University of Liverpool · 01.01.2025
DOI: 10.17638/03194582 ↗Kurz gefasst
Fachartikel in der Zeitschrift University of Liverpool, erschienen am 01.01.2025. Verfasst von Liam Farrell.
Abstract (Originalsprache)
Introduction
Biotherapeutic proteins (BPs) are a novel class of medicines used in the treatment of disease. Whilst biologics have proven clinically effective, an increasing number of adverse reactions have been observed with their increasing use. Prediction of allergic reactions to BPs at a preclinical development stage would reduce the burden on patients and prevent considerable financial loss to pharmaceutical companies. Existing commercially available assays often fail to accurately predict immunogenic profiles of BPs. As such, we aimed to develop a stepwise approach to explore immune responses to BPs by, 1) assessing the sensitivity of existing PBMC stimulation assays to BPs, 2) optimise a DC:T-cell co-culture priming assay for BPs, 3) define the immune epitopes of BPs using MHC class II restricted overlapping peptides, 4) generate aggregates to 4 BPs and assess immunogenicity in vitro.
Methods
Lymphocyte transformation tests (LTTs) and IFN-γ ELISpot assays were performed using healthy donor PBMC to assess the T-cell stimulatory capacity of a panel of BPs, with varying degrees of known immunogenicity observed in clinical settings e.g. KLH, infliximab, trastuzumab, etc. DC:T-cell co-culture methods were optimised for time-points, cell numbers and immune regulation and validated using the panel of BPs for sensitivity. 16 15-mer peptides were derived from the variable region of rituximab and epitope profiling experiments were performed using PBMC and cloned T-cells from healthy donors. Several 18-mer peptides with 2 amino acid differences were derived from AZD1402 and epitope profiling experiments were performed using PBMC and cloned T-cells from healthy donors. Aggregates were generated to infliximab using various heat and shear stress conditions. Immunogenicity was assessed using T-cell and DC stimulation assays.
Results
Initial PBMC experiments showed low sensitivity, presenting frequent false negatives. DC:T-cell assays showed Increased sensitivity to BPs, however, high background responses were observed in many of the vehicle control cultures. Further work optimising cell numbers and using immune regulatory proteins (PD-L1, CTLA4) reduced the background counts and increased the dynamic range and sensitivity of the assay. CD4+ T-cell clones were responsive to a pool of rituximab peptides in proliferation and cytokine release assays to 2/16 15-mer peptides. PBMC and CD4+ T-cell clones were responsive to AZD1402 in proliferation and cytokine release assays to 19/69 18-mer peptides, with immunogenicity clearly discernible in 3 regions of AZD1402. Aggregates were generated to infliximab and three other BPs using various heat and shear stress conditions and confirmed with size exclusion chromatography. Heat stress (infliximab) and Shear stress (adalimumab, rituximab and AZD1402) aggregates stimulated proliferation and cytokine secretion in T-cell priming and PBMC cultures, whilst also modulating maturation of DCs/monocytes.
Conclusion
PBMC and DC:T-cell assays currently lack sensitivity, meaning true levels of T-cell activation may be underrepresented in these assays. Single peptide assays clearly present the highest sensitivity in predicting immune reactions to a BP, although these results may overestimate the level of HLA-binding peptides presented by antigen presenting cells in vivo. Aggregates were generated to BPs, several of which clearly stimulate T-cells and DCs more than the monomeric forms. Overall, these data present promising advances in in vitro cell culture methods that may be used to predict immunogenicity to BPs.
Schlagwörter
Zitieren
APA
Farrell, L. (2025). Interrogating the potential of in vitro tools for predicting immunogenicity against novel modality therapeutics. University of Liverpool. https://doi.org/10.17638/03194582
Vancouver
Farrell L. Interrogating the potential of in vitro tools for predicting immunogenicity against novel modality therapeutics. University of Liverpool. 2025. doi:10.17638/03194582
BibTeX
@article{Farrell2025,
author = {Farrell, Liam},
title = {Interrogating the potential of in vitro tools for predicting immunogenicity against novel modality therapeutics},
journal = {University of Liverpool},
year = {2025},
doi = {10.17638/03194582}
}
EUVIMED